200 related articles for article (PubMed ID: 24311063)
1. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis.
Hefter H; Spiess C; Rosenthal D
J Neural Transm (Vienna); 2014 May; 121(5):513-9. PubMed ID: 24311063
[TBL] [Abstract][Full Text] [Related]
2. The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia.
Hefter H; Samadzazeh S; Rosenthal D
J Neurol; 2021 Jan; 268(1):206-213. PubMed ID: 32761340
[TBL] [Abstract][Full Text] [Related]
3. Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA.
Hefter H; Samadzadeh S; Moll M
Toxins (Basel); 2020 Oct; 12(11):. PubMed ID: 33121133
[TBL] [Abstract][Full Text] [Related]
4. The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.
Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357965
[TBL] [Abstract][Full Text] [Related]
5. Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.
Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051021
[TBL] [Abstract][Full Text] [Related]
6. Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study.
Colosimo C; Charles D; Misra VP; Maisonobe P; Om S;
J Neurol Sci; 2020 Sep; 416():117015. PubMed ID: 32682125
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A and cervical dystonia: a seven-year follow-up.
Camargo CH; Teive HA; Becker N; Munhoz RP; Werneck LC
Arq Neuropsiquiatr; 2011 Oct; 69(5):745-50. PubMed ID: 22042174
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study.
Hefter H; Samadzadeh S
Toxins (Basel); 2023 Sep; 15(10):. PubMed ID: 37888623
[TBL] [Abstract][Full Text] [Related]
9. Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.
Coleman C; Hubble J; Schwab J; Beffy JL; Picaut P; Morte C
Int J Neurosci; 2012 Jul; 122(7):358-62. PubMed ID: 22356470
[TBL] [Abstract][Full Text] [Related]
10. Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US.
Hull M; Anupindi VR; DeKoven M; He J; Bouchard J
Adv Ther; 2023 Sep; 40(9):3986-4003. PubMed ID: 37414904
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study.
Jost WH; Schramm A; Müngersdorf M; Stenner A; Schwingenschuh P; Maisonobe P; Koch M; Haslinger B
J Neurol Sci; 2019 Apr; 399():44-50. PubMed ID: 30771702
[TBL] [Abstract][Full Text] [Related]
12. Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study.
Ruiz PJ; Castrillo JC; Burguera JA; Campos V; Castro A; Cancho E; Chacón J; Vara JH; del Val JL; Garcia EL; Miquel F; Sanz P; Vela L
J Neurol; 2011 Jun; 258(6):1055-7. PubMed ID: 21197540
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study.
Moll M; Rosenthal D; Hefter H
Parkinsonism Relat Disord; 2018 Dec; 57():63-67. PubMed ID: 30150129
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
Dressler D; Bigalke H; Benecke R
J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
16. The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot Study.
Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056396
[No Abstract] [Full Text] [Related]
17. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin.
Misra VP; Colosimo C; Charles D; Chung TM; Maisonobe P; Om S;
J Neurol; 2018 Feb; 265(2):402-409. PubMed ID: 29270685
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
Dressler D; Bigalke H
J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
[TBL] [Abstract][Full Text] [Related]
19. Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study.
Hefter H; Schomaecker I; Schomaecker M; Ürer B; Brauns R; Rosenthal D; Albrecht P; Samadzadeh S
Toxins (Basel); 2023 Jun; 15(7):. PubMed ID: 37505701
[TBL] [Abstract][Full Text] [Related]
20. "Pseudo"-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study.
Hefter H; Rosenthal D; Samadzadeh S
Toxins (Basel); 2023 Oct; 15(10):. PubMed ID: 37888649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
